Literature DB >> 15931701

Endotoxin in patients with terminal renal failure undergoing dialysis with re-processing dialyser.

H M S Markum1, Herdiman T Pohan, Aida Lydia, Katsuya Inada.   

Abstract

AIM: to determine the level of endotoxin in the blood of patients with renal failure prior to and following hemodialysis using re-processing dialyser to know possibility of pyrogenic reactions in hemodialysis patients.
METHODS: this study subjects consisted of 10 patients with terminal renal failure undergoing regular hemodialysis. The collected samples were then sent in frozen condition for endotoxin examination in Japan. The normal level of endotoxin in the blood was < 9.8 pg/ml based on standard E.Coli E.0111 endotoxin quantitatively measured using Limulus Amoebocyte lysate test (the endospecy test). Statistical analysis was performed using paired student test.
RESULTS: Ten patients with terminal renal failure who were undergoing hemodialysis were obtained, consisting of 1 female and 9 males. The mean age was 55.5 years (SD 6.74), the mean hemoglobin level 7.26 g/dl (SD 2.19), mean white blood cell (WBC) count 8660/mm(3) (SD 3064.2), and mean albumin level 3.59 g/l (SD 247). The etiologies of renal failure were as follows: glomerulonephritis (GN) 30%, Diabetic nephropathy (DN) 20%, hypertension (HT) 10%, interstitial nephritis (IN) 10%, obstruction/infection (01) 10%, unknown (U) 10%. The mean duration of hemodialysis was 97.9 month (SD 54.86). The mean endotoxin level prior to hemodialysis (ET pre-hemodialysis) was 5.4 pg/dl (SD 8).
CONCLUSION: we conclude that terminal renal patients who undergoing re-processing hemodialysis did not have endotoxemia both prior to and following hemodialysis unless if they associated with infection, or other complications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15931701

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  6 in total

1.  Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Christopher W McIntyre; Laura E A Harrison; M Tarek Eldehni; Helen J Jefferies; Cheuk-Chun Szeto; Stephen G John; Mhairi K Sigrist; James O Burton; Daljit Hothi; Shvan Korsheed; Paul J Owen; Ka-Bik Lai; Philip K T Li
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

2.  The impact of antihypertensive drug therapy on endotoxemia in elderly patients with chronic kidney disease.

Authors:  Stephen G John; Paul J Owen; Laura E A Harrison; Cheuk-Chun Szeto; Ka-Bik Lai; Philip K T Li; Christopher W McIntyre
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 8.237

3.  Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients.

Authors:  Cheuk-Chun Szeto; Bonnie Ching-Ha Kwan; Kai-Ming Chow; Ka-Bik Lai; Kwok-Yi Chung; Chi-Bon Leung; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

4.  A comparative study of blood endotoxin detection in haemodialysis patients.

Authors:  Jonathan Wong; Nathan Davies; Hasan Jeraj; Enric Vilar; Adie Viljoen; Ken Farrington
Journal:  J Inflamm (Lond)       Date:  2016-07-30       Impact factor: 4.981

5.  Effect of a Hemodialysis Session on Markers of Inflammation and Endotoxin.

Authors:  Shyam Dheda; David A Vesey; Carmel Hawley; David W Johnson; Magid Fahim
Journal:  Int J Inflam       Date:  2022-03-10

Review 6.  Intestinal Barrier Disturbances in Haemodialysis Patients: Mechanisms, Consequences, and Therapeutic Options.

Authors:  D S March; M P M Graham-Brown; C M Stover; N C Bishop; J O Burton
Journal:  Biomed Res Int       Date:  2017-01-17       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.